Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions—Part II

Parish, Sharon J.; Goldstein, Andrew T.; Goldstein, S.; Goldstein, Irwin; Pfaus, James G.; Clayton, Anita H.; Giraldi, Annamaria; Simon, James A.; Althof, Stanley E.; Bachmann, Gloria; Komisaruk, Barry R.; Levin, Roy J.; Spadt, Susan Kellogg; Kingsberg, Sheryl A.; Perelman, Michael A.; Waldinger, Marcel D.; Whipple, Beverly

doi:10.1016/j.jsxm.2016.09.020

Cited by 139 publications

(84 citation statements)

References 156 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…FSD was defined as the difficulty in sexual response cycle as genital arousal disorder, female orgasmic disorder, hypoactive sexual desire, causing negative impact on quality of life and personal relationships [5,6,7]. …”

Section: Introductionmentioning

confidence: 99%

The Impact of Metabolic Syndrome and Its Components on Female Sexual Dysfunction: A Narrative Mini-Review

et al. 2019

View full text Add to dashboard Cite

Background: The impact of metabolic syndrome on female sexual dysfunction received modest consideration in clinical practice. The aim of the research was to analyze the international literature to determine the relationship between the metabolic syndrome, its components and female sexual disorders. Methods: We identified relevant full-length papers by electronic databases as Index Medicus/Medline, Scopus, Life Science Journals, from 2005 to the present. Studies were searched using the following as search query: metabolic syndrome, female sexual dysfunction, obesity, systemic arterial hypertension, diabetes mellitus, dyslipidemia. Results: Women with metabolic syndrome showed higher prevalence of sexual inactivity and low sexual desire, orgasm and satisfaction respect to women without metabolic syndrome. Particularly metabolic components as diabetes mellitus, dy-slipidemia, systemic arterial hypertension were strongly associated with lower sexual desire, activity and Female Sexual Function Index total score. In contrast, other studies showed no relationship. Conclusion: Our study showed that in the clinical evaluation of women with metabolic syndrome routine inquiring about female sexual dysfunction should be recommended to ameliorate sexual function and quality of life. However more prospective and longitudinal studies on the sexual effects of metabolic syndrome should also be suggested to know the factors related to women's sexuality better.

show abstract

Section: Introductionmentioning

confidence: 99%

The Impact of Metabolic Syndrome and Its Components on Female Sexual Dysfunction: A Narrative Mini-Review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…lifelong vs acquired; generalized vs. situational, should be retained and utilized to further categorize and stratify treatments for HSDD and other female sexual disorders/ dysfunctions [10]. d The diagnosis of HSDD in clinical practice should be based on thorough clinical assessment [11] guided by available diagnostic criteria such as ISSWSH [12,13] or the International Classification of Diseases 11th Edition [14] (Expert Opinion).…”

Section: Recommendations For the Terminology For Female Sexual Functimentioning

confidence: 99%

Global Consensus Position Statement on the use of Testosterone Therapy for Women

et al. 2019

Self Cite

View full text Add to dashboard Cite

“…[4][5][6] HSDD is characterized by low sexual desire and associated distress. [7][8][9] Although antagonist. 13,14 The function of flibanserin at these post-synaptic receptors is hypothesized to increase dopamine and norepinephrine in the prefrontal cortex and decrease serotonin 15,16 ; all three neuromodulators are thought to play key roles in the regulation of sexual arousal and desire.…”

Section: What Is Known and Objectivementioning

confidence: 99%

“…[4][5][6] HSDD is characterized by low sexual desire and associated distress. [7][8][9] Although the most recent edition of the psychiatric Diagnostic and Statistical Manual of Mental Disorders (DSM-5) combined HSDD and female sexual arousal disorder into a single diagnostic category (female sexual interest/ arousal disorder), 10,11 the International Classification of Diseases (ICD-10 and the forthcoming ICD-11) includes a diagnostic code for HSDD (F52.0 in ICD-10). 12 Specifically, the ICD-11 beta draft defines HSDD as an "absence or marked reduction in desire or motivation to engage in sexual activity as manifested by any of the following: (i) reduced or absent spontaneous desire (sexual thoughts or fantasies); (ii) reduced or absent responsive desire to erotic cues and stimulation; or (iii) inability to sustain desire or interest during sexual activity.…”

Section: What Is Known and Objectivementioning

confidence: 99%

The pharmacodynamic effects of combined administration of flibanserin and alcohol

et al. 2017

View full text Add to dashboard Cite

SummaryWhat is known and objective: Flibanserin is a serotonin 5-HT 1A agonist and 5-HT 2A antagonist approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Because of the increased risk of hypotension-and syncope-related adverse events (AEs) observed with coadministration of flibanserin and alcohol, alcohol use is contraindicated. To provide a more comprehensive understanding of the interaction between flibanserin and alcohol, the results of a dedicated phase 1 alcohol-interaction study and a pooled analysis of phase 3 studies of premenopausal women with HSDD are presented. Methods: In the phase 1 study, healthy participants (males [n=23] and females [n=2])were randomly assigned to one of five sequence groups, which determined the order in which they were to receive flibanserin 100 mg or placebo, with or without ethanol 0.4 g/kg or 0.8 g/kg. Change from baseline in seated blood pressure, orthostatic vital signs, AEs and visual analogue scale sedation outcomes were examined. Blood samples were collected at baseline and for up to 4 hours after dosing to determine flibanserin area under the plasma concentration-time curve from 0 to 4 hours (AUC 0-4 ).Pooled data from five phase 3 studies of patients receiving flibanserin 100 mg once daily (n=1543), or placebo (n=1905), were analysed. Results:In the phase 1 study, the incidence of hypotension and syncope increased when flibanserin was coadministered with ethanol. Sedation increased 20% and 27% from baseline with flibanserin plus ethanol 0.4 g/kg and 0.8 g/kg, respectively, at 4 hours post-dose. In the pooled analysis of phase 3 studies, 58.2% and 63.6% of participants receiving flibanserin or placebo, respectively, reported baseline alcohol use. In patients receiving flibanserin, fatigue and dizziness occurred more frequently in patients with vs. without alcohol use. What is new and conclusion:Results from this study suggest that increased incidence of hypotension-and syncope-related events may result from a pharmacodynamic interaction between flibanserin and alcohol, although the clinical significance of these interactions in real-world populations remains unclear. K E Y W O R D Sadditive pharmacodynamic effects, central nervous system depression, ethanol, flibanserin, hypotension, syncopeThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

show abstract

Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions—Part II

Abstract: Definitions for female sexual dysfunctions that reflect current science provide useful nomenclature for current and future management of women with sexual disorders and development of new therapies.

Cited by 139 publications

References 156 publications

The Impact of Metabolic Syndrome and Its Components on Female Sexual Dysfunction: A Narrative Mini-Review

The Impact of Metabolic Syndrome and Its Components on Female Sexual Dysfunction: A Narrative Mini-Review

Global Consensus Position Statement on the use of Testosterone Therapy for Women

The pharmacodynamic effects of combined administration of flibanserin and alcohol

Contact Info

Product

Resources

About